Effects of bevacizumab on autocrine VEGF stimulation in bladder cancer cell lines

Urologia Internationalis

Volumn 86, Issue 1, 2011, Pages 95-101

  Videira, Paula A ^a   Piteira, A Rita ^a   Cabral, M Guadalupe ^a   Martins, Catarina ^a   Correia, Manuela ^a   Severino, Paulo ^a   Gouveia, Helena ^a   Carrascal, Mylène ^a   Almeida, Joana F ^a   Trindade, Hélder ^a   Santos, Lúcio Lara ^b  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Bevacizumab; Bladder cancer; Cancer cell lines; Vascular endothelial growth factor A

Indexed keywords

BEVACIZUMAB; CAMPTOTHECIN; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADAPTATION; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951812607     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321905     Document Type: Article

References (9)

1. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
2. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858. (Pubitemid 19162712)
3. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-14.
4. Wey JS, Stoeltzing O, Ellis LM: Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin Adv Hematol Oncol 2004; 2: 37-45.
5. Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24: 8025-8037. (Pubitemid 41746746)
6. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5285. (Pubitemid 27516364)
7. Black PC, Dinney CP: Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Rev 2007; 26: 623-634. (Pubitemid 350115114)
8. Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, Kraemer K, Fuessel S, Toma M, Schwenzer B, Meye A, Grimm MO, Hakenberg OW, Jocham D, Wirth MP: Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008; 32: 1049-1056.
9. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T, Kanayama HO: Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009; 83: 98-106.